Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602173 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
A NA study of Intermittent Claudication, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00602173: Completed NA study of Intermittent Claudication, sponsored by Roxane Laboratories.
NCT00602173 is a NA study of Intermittent Claudication that has completed, run by Roxane Laboratories. The registered enrollment target is 32 participants, below the 213-participant average among 11 other Intermittent Claudication trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602173, a NA study of Intermittent Claudication, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
Conditions Studied
Interventions
- DRUG Cilostazol
Study Locations (1)
Texas
- CEDRA Clinical Research, LLC - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-05 |
| Est. Completion | 2003-05 |
| Phase | NA |
What the finished NCT00602173 record still lists
NCT00602173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 213-participant average among 11 other Intermittent Claudication trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Intermittent Claudication appearing as the primary indexed condition, and to 1 intervention - of which Cilostazol is the first listed.
NCT00602173 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00602173 about?
NCT00602173 is a clinical study titled "Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
What is the current status of trial NCT00602173?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2003-05. Estimated completion is 2003-05.
What conditions does trial NCT00602173 study?
This clinical trial studies the following conditions: Intermittent Claudication.
What interventions are being tested in trial NCT00602173?
The interventions under investigation include: Cilostazol (DRUG).
Who is sponsoring clinical trial NCT00602173?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00602173 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intermittent Claudication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00602173's enrollment target sits among peer trials
32 10th of 11 higher than 2 of 11 other Intermittent Claudication trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Intermittent Claudication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Chocolate Touch Study
ACTIVE NOT RECRUITING · NA
-
Ischemic Preconditioning Claudication Study
COMPLETED · NA
-
Exercise Training for Patients With Poor Leg Circulation
COMPLETED · NA
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia